Shandong vaccine production firm expands footprint in Weihai

At the Litong Vaccine Industrial Park in Shandong's Weihai, a vaccine production workshop is taking shape. [Photo by Gao Xin for chinadaily.com.cn]

At the Litong Vaccine Industrial Park in Shandong's Weihai, a vaccine production workshop has begun to take shape. This facility will serve as a technological research platform for classic vaccines, with a production capacity of 40 million doses per year.

At the production workshop, workers are busy with the final stages of purification work in the CMP purification workshop, including the installation of purification panels, equipment power piping, fire piping, and more. Subsequently, they will proceed with the installation, debugging, and validation of production equipment. The project is expected to be ready for operation around October of this year, allowing for herpes vaccine-related process experiments to commence by the end of the year.

The workshop is funded and constructed by Shandong Weigao Litong Biological Products Co Ltd and will serve as a crucial support for the company in expanding its reach into the development of cancer vaccines, major infectious disease vaccines, and vaccines for emerging diseases.

"After the project is completed, we will be able to simultaneously carry out process development and clinical research for nucleic acid vaccines and classic vaccine technology projects," said Wang Gang, general manager of Shandong Weigao Litong Biological Products Co Ltd.

Wang added that the workshop is expected to create a platform for the company to promote the research and development of innovative vaccines and conduct related clinical trials. (Edited by Xie Zhenzhen)